By Fineline Cube Beijing Avistone Biotechnology Co., Ltd. announced that its self-developed EGFR exon 20 insertion (ex20ins) inhibitor, andatinib benzoate capsules (PLB-1004), has received conditional market approval from China’s National Medical Products Administration (NMPA) for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring EGFR ex20ins mutations who have progressed on or are intolerant to platinum-based chemotherapy.
Regulatory Milestone
| Item | Detail |
|---|---|
| Agency | National Medical Products Administration (NMPA), China |
| Approval Type | Conditional market approval |
| Product | Andatinib benzoate capsules (PLB-1004) |
| Indication | EGFR ex20ins-mutant NSCLC post-platinum chemotherapy |
| Patient Population | Locally advanced or metastatic NSCLC with EGFR ex20ins mutations |
| Development Status | First-in-class approval in China for this specific molecular subtype |
Disease Context & Unmet Need
| Aspect | Analysis |
|---|---|
| EGFR ex20ins Prevalence | 0.3%-2.9% of all NSCLC patients in China; 2%-5% of EGFR-mutated NSCLC cases |
| Current Treatment Challenge | Intrinsic resistance to first-, second-, and third-generation EGFR-TKIs due to unique molecular structure |
| Post-Chemotherapy Outcomes | Median progression-free survival (PFS) of only 2-4 months after platinum-based chemotherapy |
| Clinical Gap | Severe lack of effective targeted therapy options represents significant unmet medical need |
| Market Opportunity | Addresses approximately 8,000-15,000 annual incident cases in China with high unmet need |
Drug Profile & Key Characteristics
Andatinib Benzoate (PLB-1004)
- Mechanism: Highly selective small-molecule EGFR inhibitor with global intellectual property rights
- Blood-Brain Barrier Penetration: Specifically designed to effectively reach the central nervous system, addressing brain metastases common in NSCLC
- High Selectivity: Preclinical studies demonstrate effective and irreversible targeting of EGFR ex20ins mutations
- Broad Spectrum Activity: Beyond ex20ins, shows potent activity against other EGFR mutation types including PACC, Del19, L858R, and T790M
Therapeutic Advantages
- First-in-Class Potential: Addresses molecular subtype previously resistant to standard EGFR-TKIs
- CNS Efficacy: Blood-brain barrier penetration provides advantage over competitors lacking CNS activity
- Mutation Coverage: Broad spectrum activity creates potential for expanded indications beyond ex20ins
Strategic Implications & Commercial Outlook
- Domestic Innovation Leadership: Represents China’s advancement in precision oncology with globally protected intellectual property
- Precision Medicine Adoption: Approval supports growing implementation of comprehensive genomic profiling in Chinese NSCLC care
- Commercial Infrastructure: Avistone can leverage existing oncology commercial networks and hospital formulary access
- Global Expansion Potential: Strong clinical profile and IP protection support international partnership opportunities
- Pipeline Validation: Success validates Avistone’s targeted therapy discovery platform and structure-based drug design capabilities
Forward‑Looking Statements
This brief contains forward-looking statements regarding commercial launch timelines, market adoption rates, and regulatory pathways. Actual results may differ due to risks including competitive developments, pricing negotiations, reimbursement decisions, and real-world clinical outcomes.-Fineline Info & Tech